ROLE OF INOSINE PRANOBEX IN MANAGEMENT OF HPV-ASSOCIATED DISEASES: PROBLEMS AND PROSPECTIVE
https://doi.org/10.17749/2313-7347.2016.10.2.076-084
Abstract
The prevalence of HPV in Russia and the world is quite high, although epidemiological data are limited because morbidity rate of papillomatosis, particularly genital warts, are not clear. The most effective method of preventing infection is vaccination against HPV infection. One of the most effective preventive measure to reduce the risk of death from HPV-related cancer diseases is a regular screening. None of the treatments of HPV infection will not totally effective and will not prevent disease transmission. In most cases, treatment is aimed at getting rid of symptoms but not cure infection. Immunomodulators for management of HPV-associated diseases could not have evidence base. Clinically proven treatment with inosine pranobex eliminates HPV to 98% cases and 3 times reduce frequency of relapses in combined therapy. Correct and complete counseling, aimed at informing the patient about the connection of HPV infection and cancer, as well as the possibility of preventing infection by timely vaccination and proper compliance are issue at present time. Isoprinosine saves a woman from the HPV, reducing the possibility of recurrence and malignancy, only when patient has complete course of therapy.
About the Authors
V. O. Bitsadze
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Bitsadze Victoria Omarovna – MD, Professor, Department of Obstetrics and Gynecology.
Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048.
N. M. Khamani
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Khamani Nadin Moktarovna – graduate student of the Department of Obstetrics and Gynecology.
Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048.
N. A. Makatsariya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Makatsariya Nataliya Aleksandrovna – Assistant of the Department of Obstetrics and Gynecology.
Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048.
References
1. Vinogradova Yu.G., Frolova N.V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2013; 1: 22
2. Gardasil. Instruction for medical use [Gardasil. Instruktsiya po meditsinskomu primeneniyu (in Russian)]. http://www.grls.rosminzdrav.ru. Accessed: 12.05.2016.
3. Dizhevskaya E.V., Blinov D.V. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2011; 4: 48-56.
4. Eliseeva M.Yu., Mynbaev O.A. Ginekologiya. 2007; 11(5): 22-33.
5. Isoprinosine. Instruction for medical use [Izoprinozin. Instruktsiya po meditsinskomu primeneniyu (in Russian)]. http://www.grls. rosminzdrav.ru. Accessed: 12.05.2016.
6. Kaprin A.D., Starinskii V.V., Petrova G.V. Status of cancer care the population of Russia in 2014 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2014 g. (in Russian)] Moscow. 2015.
7. Karaulov A.V., Blinov D.V. Vaktsinatsiya. 2011; 1: 37-42.
8. Kachalina T.S., Shakhova N.M., Kachalina O.V., Eliseeva D.D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 6-12.
9. Kedrova A.G., Levakov S.A., Tsarenko M.D. Opukholi zhenskoi reproduktivnoi sistemy. 2016; 2 (12): 77-83. 10. Kostava M.N., Prilepskaya VN. Rus. med. zhurn. 2009; 17 (1): 16-9.
10. Kotrekhova L.P., Raznatovskii K.I. Lechashchii Vrach. 2007; 9.
11. Osidak L.V., Obraztsova E.V. Lechashchii vrach. 2012; 10 (12): 116.
12. Prilepskaya V.N., Dovletkhanova E.R., Abakarova P.R. Akusherstvo i ginekologiya. 2011; 5: 123-128.
13. Prilepskaya V.N., Rogovskaya S.I. RMZh. 2007; 16 (3): 14.
14. Prilepskaya V.N. Prevention of cervical cancer. Achievements and Prospects. XI All-Russian Scientific Forum "Mother and Child - 2010". Satellite Symposium "Cervical cancer: prospects and reality for primary prevention." [Profilaktika raka sheiki matki. Dostizheniya i perspektivy. XI vserossiiskii nauchnyi forum «Mat' i Ditya – 2010». Satellitnyi simpozium «Rak sheiki matki: perspektivy i real'nost' pervichnoi profilaktiki» (in Russian)]. September, 2010.
15. Prilepskaya V.N. Prevention of cervical cancer in Russia. Conference "Modern approaches to the prevention of women's cancers." [Profilaktika raka sheiki matki v Rossii. Konferentsiya «Sovremennye podkhody k profilaktike onkologicheskikh zabolevanii zhenshchin» (in Russian)]. SPb. 11 December, 2010.
16. Prilepskaya V.N. The key problem of HPVassociated diseases: achievements and prospects. All-Russian Congress with international participation "Outpatient practice: diagnosis, treatment, prevention." Abstracts [Klyuchevaya problema VPChassotsiirovannykh zabolevanii: dostizheniya i perspektivy. Vserossiiskii kongress s mezhdunarodnym uchastiem «Ambulatornopoliklinicheskaya praktika: diagnostika, lechenie, profilaktika». Sbornik tezisov (in Russian)]. Moscow. 2016; 212 s.
17. Solov'ev A.M. Vestnik dermatologii i venerologii. 2011; 5: 146-151.
18. Solov'ev A.M., Chernova N.I. RMZh. 2015; 11: 621-625.
19. Unanyan A.L., Sidorova I.S., Kossovich Yu.M., Rzyanina Yu.A., Kadyrova A.E. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 1: 27-30.
20. The federal cancer registry of the Russian Federation [Federal'nyi rakovyi registr RF (in Russian)]. Moscow. 2015.
21. Fittspatrik D.E., Eling D.L. Secrets of dermatology [Sekrety dermatologii (in Russian)]. Moscow. 1999; 511 s.
22. Cervarix. Instruction for medical use [Tservariks. Instruktsiya po meditsinskomu primeneniyu (in Russian)].
23. Chissov V.I., Starinskii V.V., Petrova G.V. Malignancies in Russia in 2009 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2009 godu (zabolevaemost' i smertnost') (in Russian)]. Moscow. 2011. 260 s.
24. Chissov V.I., Starinskii V.V., Petrova G.V. Status of cancer care the population of Russia in 2009 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2009 godu (in Russian)]. Moscow. 2010. 196 s.
25. Aldara (imiquimod) package insert. Bristol, TN: Grace Pharmaceuticals, LLC; April 2009.
26. Arbun M. et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition. 2014.
27. Beutner K.R., Becker T.M., Stone K.M. Epidemiology of HPV infections. J. Am. Acad. Dermatol. 1988; 18: 169-172.
28. Block S.L., Nolan T., Sattler C. et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov; 118 (5): 2135-45.
29. Bonnez W., Reichman R.C. Papillomaviruses. In: Mandell GC, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Elsevier Inc. 2010; 2035-2046.
30. Campion M.J. Clinical manifestations and natural history of genital human papillomavirus infection. Obstet. Gynecol. Clin. North. Am. 1987; 14: 363-388.
31. Collins S., Mazloomzadeh S., Winter H. et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002 Jan; 109 (1): 96-98.
32. Condylox (podofilox) package insert. Corona, CA: Watson Pharmaceuticals; November 2007.
33. Epidemiology and Prevention of VaccinePreventable Diseases. The Pink Book: Course Textbook. 12th Edition. Centers for Disease Control and Prevention (CDC). http://www.cdc. gov/vaccines/pubs/pinkbook/default.htm. Data obrashcheniya: 20.06.2016.
34. Georgala S., Katoulis A., Befon A. et al. Oral inosiplex in the treatment of cervical condylomata acuminata: a randomized placebo-controlled trial. BJOG. 2006; 113 (9): 1088-91.
35. Gillison M.L. Human papillomavirusassociated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004 Dec; 31 (6): 744-54.
36. Goad J.A., Hess K.M. Sexually transmitted diseases. In: Koda-Kimble MA, Young LY, Kradjan WA, et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Baltimore, MD: Lippincott Williams & Wilkins. 2009; 65: 29-30.
37. Gordon P., Brown E. R. The antiviral activity of Isoprinosine. Can. J. Microbiol. 1972; 18: 1463-1470.
38. Guidelines for vaccinating pregnant women. Human papillomavirus (HPV). January 2010. CDC. http://www.cdc.gov/vaccines/pubs/pregguide. htm. Accessed: 26.06.2016.
39. Hayney M.S. Vaccines, toxoids, and other immunobiologics. In: DiPiro JT, Talbert RL, Yee GC et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York. 2008; 2047.
40. Hutchinson D.J., Klein K.C. Human papillomavirus disease and vaccines. Am J Health Syst Pharm. November 15, 2008; 65 (22): 2105-12.
41. Kreimer A.R., Clifford G.M., Boyle P. et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14 (2): 467-75.
42. Lacey C.J.N., Lowndes C.M., Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006 Aug 31; 24 (3): 35-41.
43. Munoz N., Bosch F.X., Castellsague. X. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20; 111 (2): 278-85.
44. Munoz N., Bosch F.X., de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
45. Paik C., Savino L.B. Prevention and treatment options for genital human papillomavirus. Am Pharm. 2007; (8): 31-39.
46. Syrjanen S.M. et al. Anal condylomas in men. Genitour. Med. 65: 1989; 216-224.
47. Winer R.L., Kiviat N.B., Hughes J.P. et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005 Mar 1; 191 (5): 731-8.
48. Winer R.L., Lee S.K., Hughes J.P. et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003 Feb 1; 157 (3): 218-26.
Review
For citations:
Bitsadze V.O., Khamani N.M., Makatsariya N.A. ROLE OF INOSINE PRANOBEX IN MANAGEMENT OF HPV-ASSOCIATED DISEASES: PROBLEMS AND PROSPECTIVE. Obstetrics, Gynecology and Reproduction. 2016;10(3):76-84. (In Russ.) https://doi.org/10.17749/2313-7347.2016.10.2.076-084
Views: 9570
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
